MOMA-341 is a highly selective inhibitor targeting the Werner RecQ-like helicase (WRN). It exerts a dual mechanism of allosteric regulation and ATP competitive inhibition by binding to the cysteine 727 site of the WRN protein. In mouse models with mismatch repair deficiency (dMMR) or high microsatellite instability (MSI-H), MOMA-341 can induce DNA damage, cell apoptosis, and promote tumor shrinkage. This compound exhibits significant anti-tumor activity and has potential application prospects in the study of advanced and metastatic solid tumors.